Cyclooxygenase Stimulated Neovascularization in Diabetic

环加氧酶刺激糖尿病的新血管形成

基本信息

  • 批准号:
    7043948
  • 负责人:
  • 金额:
    $ 30.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-09-30 至 2009-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) is the major single cause of end stage renal disease in the United States. DN is associated with vascular disease, including retinopathy, impaired wound healing and neuropathy. Although less recognized, increased glomerular neovascularization has also been observed in type 1 diabetes. However, at present it is not clear which molecular pathway/s control glomerular angiogenesis in diabetes. Cyclooxygenases (COX) 1 and 2 are key enzymes involved in the generation of prostaglandin E2 (PGE2). Notably, COX-2 is over-expressed in both renal cortex and medulla of diabetic mice. The observation that treatment of diabetic mice with COX-2 inhibitors reduces the expression of pro-angiogenesis molecules as well as albuminuria, strongly suggest a role for COX-derived prostanoids in DN. As i) increased COX expression is observed in diabetic kidneys, ii) PGE2 stimulates angiogenesis, iii) PGE2 increases endothelial permeability, and iv) the PGE2 EP4 receptor is highly expressed in glomeruli, we hypothesize that a functional prostaglandin dependent pathway is activated in diabetic kidney disease and promotes glomerular angiogenesis. To test this hypothesis we will assess 1) the contribution of COX-1 versus COX-2 derived prostanoids to the progression of neovascularization in mouse models of type I diabetes; 2) the role of a microsomal prostaglandin E2 synthase in the production of PGE2 and consequent glomerular neovascularization in type I diabetes and 3) the role of the glomerular endothelial and podocytes EP4 in the progression of diabetic. This study will enable us not only to define how COXs, PGE2 and its receptors alter glomerular microvascular angiogenesis in the setting of type 1 diabetes, but also to define whether preventing PGE2 synthesis and/or EP receptor activation might provide a specific therapeutic strategy to the treatment for altered angiogenesis in DN. This work will be a joint effort between Drs. Breyer and Pozzi. Dr. Breyer's group has been studying the roles of renal cyclooxygenase and PGE2 for over 15 years and has generated several of the transgenic mouse models used to study prostanoid function. His group also has substantial experience phenotyping mouse models of diabetic nephropathy. Dr. Pozzi studies the role of integrin (1(1, a major collagen binding receptor, in the control of endothelial cell biology and collagen homeostasis, two relevant aspects in DN. Recently she has examined the contribution of COX-2-derived PGE2 and its receptor EP4 in the control of tumor angiogenesis. Moreover, Drs. Pozzi and Breyer published in JBC an article on the role of COX-2 in the renal medullary interstitial cell survival. We believe the present proposal provides synergy between Dr. Pozzi's expertise in angiogenesis and Dr. Breyer's expertise in mouse models of diabetic nephropathy, and draws on their common interest in the prostanoid pathway in cell differentiation and survival.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Matthew Douglas Breyer其他文献

Matthew Douglas Breyer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Matthew Douglas Breyer', 18)}}的其他基金

PPARs in CYP450 Dependent Regulation of Kidney Function
CYP450 中 PPAR 的肾功能依赖性调节
  • 批准号:
    7459642
  • 财政年份:
    2007
  • 资助金额:
    $ 30.42万
  • 项目类别:
Cyclooxygenase Stimulated Neovascularization in Diabetic
环加氧酶刺激糖尿病的新血管形成
  • 批准号:
    7125564
  • 财政年份:
    2005
  • 资助金额:
    $ 30.42万
  • 项目类别:
PPARs in CYP450 Dependent Regulation of Kidney Function
CYP450 中 PPAR 的肾功能依赖性调节
  • 批准号:
    6813192
  • 财政年份:
    2004
  • 资助金额:
    $ 30.42万
  • 项目类别:
Generating Mouse Mutants with Diabetic Nephropathy
产生患有糖尿病肾病的小鼠突变体
  • 批准号:
    6524683
  • 财政年份:
    2001
  • 资助金额:
    $ 30.42万
  • 项目类别:
Generating Mouse Mutants with Diabetic Nephropathy
产生患有糖尿病肾病的小鼠突变体
  • 批准号:
    6941309
  • 财政年份:
    2001
  • 资助金额:
    $ 30.42万
  • 项目类别:
Generating Mouse Mutants with Diabetic Nephropathy
产生患有糖尿病肾病的小鼠突变体
  • 批准号:
    6442192
  • 财政年份:
    2001
  • 资助金额:
    $ 30.42万
  • 项目类别:
CYTOCHROME P-450 ARACHIDONIC ACID METABOLISM & REGULATION OF RENAL ION TRANSPORT
CYTOCHROME P-450 花生四烯酸代谢
  • 批准号:
    6564251
  • 财政年份:
    2001
  • 资助金额:
    $ 30.42万
  • 项目类别:
Generating Mouse Mutants with Diabetic Nephropathy
产生患有糖尿病肾病的小鼠突变体
  • 批准号:
    6796361
  • 财政年份:
    2001
  • 资助金额:
    $ 30.42万
  • 项目类别:
Generating Mouse Mutants with Diabetic Nephropathy
产生患有糖尿病肾病的小鼠突变体
  • 批准号:
    6663477
  • 财政年份:
    2001
  • 资助金额:
    $ 30.42万
  • 项目类别:
Generating Mouse Mutants with Diabetic Nephropathy
产生患有糖尿病肾病的小鼠突变体
  • 批准号:
    6654901
  • 财政年份:
    2001
  • 资助金额:
    $ 30.42万
  • 项目类别:

相似国自然基金

RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
  • 批准号:
    82372007
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
  • 批准号:
    82371726
  • 批准年份:
    2023
  • 资助金额:
    50.00 万元
  • 项目类别:
    面上项目
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
  • 批准号:
    81200692
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
基于新生血管显像研究MSC治疗缺血性脑血管病的转化医学关键问题
  • 批准号:
    81171370
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
探索VASH2转录激活对肝细胞癌血管生成和上皮间质转化的作用及机制
  • 批准号:
    81172267
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
解析miR-566调控VHL/β-catenin信号通路影响人脑胶质瘤血管新生的分子机制
  • 批准号:
    81101916
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
脂肪组织来源干细胞促进颗粒脂肪游离移植后再血管化机制的实验研究
  • 批准号:
    81171834
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
99mTc-3PRGD2 SPECT显像用于评价肺癌抗新生血管药物疗效的动物研究及肺癌诊断临床研究
  • 批准号:
    81171369
  • 批准年份:
    2011
  • 资助金额:
    56.0 万元
  • 项目类别:
    面上项目
核素靶向示踪肿瘤新生血管作用位点研究
  • 批准号:
    81071183
  • 批准年份:
    2010
  • 资助金额:
    32.0 万元
  • 项目类别:
    面上项目
Ihh在组织工程骨构建中作用和机制研究
  • 批准号:
    30973069
  • 批准年份:
    2009
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Igniting Life with Sparks of Light: 3D Spatiotemporal Photoactivation of Angiogenesis via Radiational Kinesis (3D SPARK)
用光的火花点燃生命:通过辐射运动进行血管生成的 3D 时空光激活 (3D SPARK)
  • 批准号:
    MR/X034976/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.42万
  • 项目类别:
    Fellowship
The impact of Hyaluronic Acid on growth factor signalling and angiogenesis
透明质酸对生长因子信号传导和血管生成的影响
  • 批准号:
    DP240101674
  • 财政年份:
    2024
  • 资助金额:
    $ 30.42万
  • 项目类别:
    Discovery Projects
Pacemakers of Cholinergic Wave Activity in the Developing Retina
视网膜发育中胆碱能波活动的起搏器
  • 批准号:
    10653330
  • 财政年份:
    2023
  • 资助金额:
    $ 30.42万
  • 项目类别:
The effect of circadian rhythm disruptions on the angiogenic response to hypoperfusion in the AD brain
昼夜节律紊乱对 AD 大脑低灌注血管生成反应的影响
  • 批准号:
    10656133
  • 财政年份:
    2023
  • 资助金额:
    $ 30.42万
  • 项目类别:
Protein tyrosine phosphatase non-receptor 14 in vascular stability and remodeling
蛋白酪氨酸磷酸酶非受体 14 在血管稳定性和重塑中的作用
  • 批准号:
    10660507
  • 财政年份:
    2023
  • 资助金额:
    $ 30.42万
  • 项目类别:
Human Plasma Cell Maturation & Maintenance through CD138, TNFRSF, and Modulation of Ig Secretion
人类浆细胞成熟
  • 批准号:
    10660723
  • 财政年份:
    2023
  • 资助金额:
    $ 30.42万
  • 项目类别:
Arginyl-tRNA beyond translation: mechanism and regulation of protein arginylation
超越翻译的精氨酰-tRNA:蛋白质精氨酰化的机制和调控
  • 批准号:
    10711167
  • 财政年份:
    2023
  • 资助金额:
    $ 30.42万
  • 项目类别:
Novel Polymer-antibody Conjugates as Long-acting Therapeutics for Ocular Diseases
新型聚合物-抗体缀合物作为眼部疾病的长效治疗药物
  • 批准号:
    10760186
  • 财政年份:
    2023
  • 资助金额:
    $ 30.42万
  • 项目类别:
Development of peptide drug conjugates for cancer therapy
开发用于癌症治疗的肽药物缀合物
  • 批准号:
    10760236
  • 财政年份:
    2023
  • 资助金额:
    $ 30.42万
  • 项目类别:
Vascular remodeling in the ovary
卵巢血管重塑
  • 批准号:
    10724873
  • 财政年份:
    2023
  • 资助金额:
    $ 30.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了